Dago Bio Completes Over $20 Million A+ Round Funding to Accelerate Novel Molecular Glue Drug Development
Dago Bio Completes Over $20 Million A+ Round Funding to Accelerate Novel Molecular Glue Drug DevelopmentLate 2024, Dago Bio (hereinafter referred to as Dago), a biotechnology company focused on developing molecular glue drugs targeting undruggable targets, announced the successful completion of a Series A+ financing round exceeding $20 million. This round was co-led by Zhejiang Province's "4+1" Biomedicine and High-end Medical Device Industry Fund, Takeda Ventures, Fengchuan Capital, Longmen Capital, HaoYue China Healthcare Fund, and AIM-HI Accelerator Fund...
Tech >>
Global First! Molecular Heart Xu Jinbo's team has opened up new algorithms to overcome the challenges of protein side chain prediction and sequence design
Recently, the team led by Molecular Heart Xu Jinbo has launched a new AI protein side chain prediction algorithm called "AttnPacker", which has achieved significant improvements in speed, memory efficiency, and overall accuracy. It is currently the best known side chain structure prediction algorithm and the world's first AI algorithm that can simultaneously predict side chains and design protein sequences...
Tech >>